Accelerate to discover

Back to filter

Related topics

Early immune response in mice immunized with inactivated vaccine against SARS-CoV-2

Cytek Biosciences

Nov 19, 2020

The development of a vaccine against COVID-19 is a hot topic for many research laboratories all over the world. Our aim...

Bruker announces software provider PMOD Technologies LLC

Bruker Biospin

Nov 13, 2020

PMOD Technologies aims to equip researchers with best-in-class software tools for biomedical imaging research in humans...

Microvascular injury in mild traumatic brain injury accelerates alzheimer-like pathogenesis in mice

RWD

Nov 9, 2020

Traumatic brain injury (TBI) is considered as the most robust environmental risk factor for Alzheimer’s disease (AD)....

Live animal imaging - Humane animal research

Bruker Biospin

Oct 26, 2020

Drawing on over 50 years of expertise in the life and animal sciences, Bruker designs preclinical imaging systems that...

Nov 24, 2020

Meet the Expert - Brent Barre interview

emka TECHNOLOGIES

Oct 21, 2020

Learn what a researcher at the forefront of COVID-19 research has to say about his current research environment.

Automated fever & hypothermia detection

emka TECHNOLOGIES

Oct 14, 2020

As one of the oldest clinical indicators of disease in mammals, temperature is a crucial parameter to monitor,...

Multi-modal molecular imaging driving pre-clinical research & pharmaceutical development

Bruker Biospin

Oct 6, 2020

Multi-modal molecular imaging at Massachusetts General Hospital – driving pre-clinical research and patient pathways...

Nov 24, 2020

Imaging Performance of a multimodal module to enhance preclinical irradiator capabilities

Precision X-Ray

Sep 15, 2020

Upgrading an existing irradiator with such a multi-modal imaging device is a reasonable investment in laboratories...

Show all topics (10)

New publication from the University of Stuttgart using Attana

Jun 14, 2016

The team of Professor Dr. Roland Kontermann at the Institute of Cell Biology and Immunology, University of Stuttgart, Germany has recently published an article in PLOS ONE titled A Fab-Selective Immunoglobulin-Binding Domain from Streptococcal Protein G with Improved Half-Life Extension Properties.
Professor Kontermann's group is working on the development of novel strategies for tumor therapy. The strategies are based on the use of specific ligands to target potent cytotoxic effector mechanism to the tumor. Their focus is on three effector arms: 1) bispecific antibodies for the retargeting of effector cells of the immune system (immunotherapy), 2) targeted carrier systems (liposomes, polymers) for drug delivery (chemotherapy), and 3) targeted cytotoxic fusion proteins (biotherapy). Main targets are molecules associated with the tumor vasculature (vascular targeting), since these structures are easily accessible for circulating agents and all solid tumors are dependent on vascularisation.
In this publication the group employed their Attana A200 system for affinity determination.

Read more

Scientific paper

Related technologies: Single-molecule Interactions

Brand profile

Attana

Attana biosensors provides a reliable, fast and versatile label-free method to study molecular interactions.

Related products

The label-free biosensor that combines biochemical and cell-based assays.

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey